Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6,466 | 3 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $6,466 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2018 | $3,490 | 2 | Celgene Corporation ($3,490) |
| 2017 | $2,976 | 1 | Celgene Corporation ($2,976) |
All Payment Transactions
3 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/01/2018 | Celgene Corporation | Pomalyst (Drug) | — | In-kind items and services | $442.00 | Research |
| Study: CC-4047-MM-007 - Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma • Category: Hematology / Oncology | ||||||
| 02/13/2018 | Celgene Corporation | Pomalyst (Drug) | — | In-kind items and services | $3,048.00 | Research |
| Study: CC-4047-MM-014 - Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab • Category: Hematology / Oncology | ||||||
| 08/02/2017 | Celgene Corporation | Pomalyst (Drug) | — | In-kind items and services | $2,976.00 | Research |
| Study: CC-4047-MM-014 • Category: Hematology / Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-4047-MM-014 - Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab | Celgene Corporation | $3,048 | 1 |
| CC-4047-MM-014 | Celgene Corporation | $2,976 | 1 |
| CC-4047-MM-007 - Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $442.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 11 | 23 | $8,805 | $1,731 |
| 2022 | 1 | 13 | 46 | $17,526 | $4,218 |
| 2021 | 1 | 14 | 26 | $8,762 | $1,966 |
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 23 | $8,805 | $1,731 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 13 | 46 | $17,526 | $4,218 | 24.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 26 | $8,762 | $1,966 | 22.4% |
About Dr. Shanthi Srinivas, M.D
Dr. Shanthi Srinivas, M.D is a Hematology & Oncology healthcare provider based in Olympia, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164446811.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shanthi Srinivas, M.D has received a total of $6,466 in payments from pharmaceutical and medical device companies, with $3,490 received in 2018. These payments were reported across 3 transactions from 1 company. The most common payment nature is "" ($6,466).
As a Medicare-enrolled provider, Srinivas has provided services to 38 Medicare beneficiaries, totaling 95 services with total Medicare billing of $7,915. Data is available for 3 years (2021–2023), covering 3 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Olympia, WA
- Active Since 07/26/2006
- Last Updated 05/06/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1164446811
Products in Payments
- Pomalyst (Drug) $6,466
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Olympia
Min Kang, Md, MD
Hematology & Oncology — Payments: $18,182
Ahmad Fora, Md, MD
Hematology & Oncology — Payments: $12,047
Dr. Vinh Trang, M.d, M.D
Hematology & Oncology — Payments: $966.73
Dr. Jennifer Dacus, Md, MD
Hematology & Oncology — Payments: $457.61
Monique Semien, Md, MD
Hematology & Oncology — Payments: $70.37